Abstract
Purpose
Axillary Lymph Node Dissection (ALND) is recommended for breast cancer patients who present with clinically node positive disease (cN1) especially if they have residual nodal disease (ypN+) following neoadjuvant therapy (NAT). It is unknown whether axillary dissection improves outcome for these patients.
Methods
A prospectively maintained database was used to identify all patients who were diagnosed with cTis-T4N1M0 breast cancer treated with NAT.
Results
In our study, of 292 cN1 breast cancer patients who received NAT, we compared ALND with targeted axillary surgery (TAS) in ypN+ patients. ALND was performed in 75% of the ypN+ subgroup, while 25% underwent TAS. Axillary recurrence occurred in four ALND patients, but no recurrence was observed in the TAS group (p = 0.21). Five-year axillary recurrence-free survival was 100% for TAS and 90% for ALND (p = 0.21). Overall survival at five years was 97% for TAS and 85% for ALND (p = 0.39). Disease-free survival rates at five years were 51% for TAS and 61% for ALND (p = 0.9). Clinicopathological variables were similar between the groups, although some differences were noted. ALND patients had smaller clinical tumor size, larger pathological tumor size, more lymph nodes retrieved, larger tumor deposits, higher rates of extranodal extension, and greater prevalence of macrometastatic nodal disease. Tumor subtype and size of lymph node tumor deposit independently predicted survival.
Conclusion
Axillary recurrence is infrequent in cN1 patients treated with NAT. Our study found that ALND did not reduce the occurrence of axillary recurrence or enhance overall survival. It is currently uncertain which patients benefit from axillary dissection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The dataset generated and analysed during the current study is not publicly available, but is available from the corresponding author on reasonable request.
References
Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461. https://doi.org/10.1001/jama.2013.278932
Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609–618. https://doi.org/10.1016/S1470-2045(13)70166-9
Boileau J-F, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33(3):258–264. https://doi.org/10.1200/JCO.2014.55.7827
Classe J-M, Loaec C, Gimbergues P et al (2019) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 173(2):343–352. https://doi.org/10.1007/s10549-018-5004-7
Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072–1078. https://doi.org/10.1200/JCO.2015.64.0094
Tee SR, Devane LA, Evoy D et al (2018) Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg 105(12):1541–1552. https://doi.org/10.1002/bjs.10986
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 19 Nov 2022
Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F et al (2021) Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol 47(4):804–812. https://doi.org/10.1016/j.ejso.2020.10.014
Wong SM, Basik M, Florianova L et al (2021) Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 28(5):2621–2629. https://doi.org/10.1245/s10434-020-09211-0
Almahariq MF, Levitin R, Quinn TJ et al (2021) Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual n1 nodal disease following neoadjuvant chemotherapy. Ann Surg Oncol 28(2):930–940. https://doi.org/10.1245/s10434-020-08928-2
Henke G, Knauer M, Ribi K et al (2018) Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials 19(1):667. https://doi.org/10.1186/s13063-018-3021-9
Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01901094. Accessed 9 May 2022
Ling DC, Iarrobino NA, Champ CE, Soran A, Beriwal S (2020) Regional recurrence rates with or without complete axillary dissection for breast cancer patients with node-positive disease on sentinel lymph node biopsy after neoadjuvant chemotherapy. Adv Radiat Oncol 5(2):163–170. https://doi.org/10.1016/j.adro.2019.09.006
Chun JW, Kim J, Chung IY et al (2021) Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy. Sci Rep 11(1):9056. https://doi.org/10.1038/s41598-021-88442-x
Konkin DE, Tyldesley S, Kennecke H, Speers CH, Olivotto IA, Davis N (2006) Management and outcomes of isolated axillary node recurrence in breast cancer. Arch Surg 141(9):867–872. https://doi.org/10.1001/archsurg.141.9.867. (discussion 872)
Langer I, Marti WR, Guller U et al (2005) Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 241(1):152–158. https://doi.org/10.1097/01.sla.0000149305.23322.3c
Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30(32):3960–3966. https://doi.org/10.1200/JCO.2011.40.8369
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dux, J., Habibi, M., Malik, H. et al. Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 202, 267–273 (2023). https://doi.org/10.1007/s10549-023-07062-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-023-07062-3